Tenaya Therapeutics Inks $1.13 Billion Deal with Alnylam for Cardiovascular Disease Targets
Event summary
- Tenaya Therapeutics and Alnylam Pharmaceuticals entered a research collaboration to identify novel genetic targets for cardiovascular disease therapeutics.
- Tenaya will receive up to $10 million in upfront payments plus research funding, with potential milestone payments totaling $1.13 billion.
- The agreement focuses on validating up to 15 gene targets over two years using Tenaya’s proprietary target identification and validation capabilities.
- Alnylam will handle development and commercialization of any therapeutics derived from the identified targets.
The big picture
This collaboration underscores Tenaya’s strategy of leveraging human genetics for cardiovascular disease treatments. The partnership with Alnylam, a leader in RNA interference therapeutics, highlights the growing trend of biotech companies combining specialized capabilities to accelerate drug discovery and development. The deal size—up to $1.13 billion in milestone payments—reflects the high stakes in developing transformative therapies for heart disease.
What we're watching
- Execution Risk
- Whether Tenaya can successfully validate the targeted gene candidates within the two-year timeframe.
- Pipeline Expansion
- How this collaboration will impact Tenaya’s existing pipeline and its focus on other cardiovascular conditions.
- Market Impact
- The potential market reaction to the deal, given the significant milestone payments at stake.
Related topics